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IntrOductIOn
Cisplatin has been used in the treatment of many solid-organ 
malignancies, including head, neck, lung, breast, testis and ovary 
cancers [1,2]. Nephrotoxicity is the most important side effects of 
Cisplatin, but neurotoxicity, myelosupression, ototoxicity and allergic 
reactions are its other side effects [3]. Renal vasoconstriction, 
hypomagnesaemia, hypocalcaemia, urinary concentration defect, 
Fancony-like syndrome and distal RTA, are some common Cisplatin 
renal side effects [4-7]. In addition, it can cause acute and chronic 
renal failure. Several days after the prescription of the drug, non-
oliguric renal failure may occur. Partial or complete recovery of renal 
function usually occurs after two to four weeks. Repeated usage of 
the drug can cause permanent renal failure. High dose and frequent 
use of this drug increase nephrotoxicity risk. High age, femaleness, 
baseline renal insufficiency and hypo-Albuminuria are probable 
risk factors of nephrotoxicity [8,9]. Excretion of the Cisplatin from 
the body occurs as glomerular filtration and tubular secretion [10]. 
Cisplatin increased blood level of pro-inflammatory cytokines, such 
as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), 
so damage to kidney occur via its oxidative property and probably 
with apoptotic pathway [11-13].
Some strategies, such as administration of lower dose of drug, 
vitamin C, selenium, N-acetylcysteine (NAC) and theophylline have 
been used for Cisplatin nephrotoxicity prevention [14-17]. Recently, 
Silymarin have been used in some experimental studies for Cisplatin 
nephrotoxicity prevention [18,19].
Silybum marianum is a herbal drug containing Silymarin, composed 
of flavanol lignans silybin (the most biologically active component), 
Silychristine and Silydianin [20]. Several mechanisms were described 
for Silymarin effects, including anti-oxidation, inhibition of lipid 
peroxidation, immunomodulation and anti-inflammatory effects [21-
23]. Silymarin 140 mg, two to three times daily, is the recommended 
dose in adults that has significant anti-inflammatory effect [24].
 
Both animal and human studies have shown safety profile of 
Silymarin usage. A few mild adverse effects were reported, including 
mild allergic reactions or diarrhea in high dose consumption [25]. 
Because of its safety profile, low cost, and its easy availability, 
several studies have been performed about the effects of Silymarin 
on different diseases. For example, Silymarin has been used in a 
variety of liver diseases, including acute and chronic hepatitis, 
alcoholic hepatitis, and fatty liver. Hepato-protective property of 
Silymarin might be due to several mechanism including; inhibition of 
lipid peroxidation, anti-inflammation, increase of detoxification, anti-
oxidation and immmuno-modulatory effects [24]. 
Renoprotective effect of Silymarin was studied mainly in rats. In some 
of these studies, Silymarin was shown to have positive effects on 
preventing or decreasing severity of Cisplatin nephrotoxicity [18,19]. 
Therefore, the aim of this study was to evaluate the protective effect 
of Silymarin on Cisplatin nephrotoxicity in adults with malignancy. 
MAterIAls And MethOds
In a clinical trial study, 60 patients with malignancy, candidate 
of Cisplatin administration were randomly enrolled in two equal 
groups. 
Inclusion criteria were: age more than 18-year-old, normal liver 
function tests, GFR>60ml/min or serum Cr<2mg/dl. 
Exclusion criteria were: use of nephrotoxic drugs as aminoglycoside 
or intravenous contrast media, new use of angiotensin converting 
enzyme inhibitors or angiotensin receptors blockers, significant 
impair cardiac function (dyspnea on exertion> NYHA class two), 
acute renal failure need to dialysis during the study, uncoopration 
of patients). 
Case group patients, was received Silymarin tablet 140 mg/bid 7 
days before Cisplatin administration together with Cisplatin, and 
in control group, Cisplatin was prescribed. Two groups of patients 
were matched based on Cisplatin total dose and duration of 
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ABstrAct
Background: Reno-protective effect of Silymarin was studied in 
some studies mainly on rats. In some of these studies, Silymarin 
was shown to have positive effects on preventing or decreasing 
severity of Cisplatin nephrotoxicity. 
Objective: The aim of this study was to evaluate the protective 
effect of Silymarin on Cisplatin nephrotoxicity in adult patients 
with malignancy. 
Materials and Methods: In this clinical trial study, 60 patients 
with malignancy, candidate of Cisplatin treatment were ran-
domly enrolled in two equal groups. In patients of case group, 
Silymarin tablet 140 mg/bid was administrated seven days be-
fore Cisplatin administration together with Cisplatin, and in con-
trol group, Cisplatin was prescribed. Blood Urea Nitrogen (BUN) 
and serum Creatinine (Cr) were checked at the same day and 3 
and 7 days after administration of Cisplatin.
results: Mean age of the patients in case and control groups 
were 51.1±14.3 y and 51.1±13.7 y respectively (p=0.99). There 
was no significant difference based on BUN and serum Cr in 
the beginning of study and three days after administration of 
Cisplatin in two groups of patients; however, after two weeks, 
BUN and serum Cr were significantly lower in the case group 
compared to the control group. Also, in the case group, BUN 
and serum Cr decreased and in the control group, they increased 
after two weeks after Cisplatin administration.  
conclusion: This study showed that Silymarin can decrease 
Cisplatin nephrotoxicity, so because of safety profile and 
minor adverse effect of Silymarin, we can use it as prophylaxis 
against Cisplatin nephrotoxicity in various Cisplatin-contained 
chemotherapy regimens.
Ali Momeni et al., Silymarin and Cisplatin nephrotoxicity www.jcdr.net
Journal of Clinical and Diagnostic Research. 2015 Apr, Vol-9(4): OC11-OC1312
chemotherapy. Blood Urea Nitrogen (BUN), serum Creatinine (Cr), 
Alanine transaminase (ALT), Aspartate transaminase (AST),Complete 
Blood Count (CBC) were checked at the same day and 3 and 7 
days after administration of Cisplatin. It has been explained to the 
patients that all information will remain confidential. Besides, written 
consent forms were filled in by all cases. The results were expressed 
as mean ± standard deviation (SD) and the analysis was done by 
SPSS using Chi-square and independent t-test. 
results
In this study, 60 patients were enrolled in two equal case and 
control groups. There were 6 (20%) males and 24 (80%) females in 
case group, whereas there were 11 (37%) and 19 (63%) in control 
group, respectively. Mean age of the patients in case and control 
groups were 51.1±14.3 y and 51.1±13.7 y, respectively (p=0.99). 
As mentioned in [Table/Fig-1], there was no significant difference 
based on BUN and serum Cr in the beginning of the study and 
three days after administration of Cisplatin in two groups of patients; 
however, after two weeks, BUN and serum Cr were significantly 
lower in the case group compared to the control group. Serum Cr 
was 0.93±0.18 mg at the beginning of the study and increased 
up to 0.80±0.19 mg after two weeks in case group (p<0.001), but 
in the control group, it was 0.86±0.13 mg at the beginning and 
increased up to 1±0.26 mg after two weeks (p=0.003) [Table/Fig-2]. 
In addition, in the case group, serum BUN was 15.6±5 mg at the 
beginning of the study, and decreased to 14±4.2 mg after two 
weeks (p=0.003), but in the control group, they were 16.2±7.9 mg 
and 18±8.8 mg at the beginning and two weeks later, respectively 
(p=0.037) [Table/Fig-3].In summary, in case group, BUN and serum 
Cr were decreased; however they were increased in control group 
two weeks after Cisplatin administration.
no study has been carried out about the effect of Silymarin on 
Cisplatin nephrotoxicity in human and just a few studies were done 
on animals on laboratory media. For example Turgut F et al., found 
that Silymarin can reduce reperfusion injury of kidney by decreasing 
serum enzymatic activities of superoxide dismutase and glutathione 
peroxidase and increasing serum and tissue anti-oxidant [18]. 
Mansour et al., in an animal study concluded that, administration 
of Silymarin has a protective effect against Cisplatin hepatotoxicity. 
Possible mechanism of protective effect is its antioxidant property, 
glutathione levels preservation and lipid peroxidation inhibitor [19]. 
Karimi et al., also showed a protective effect of Silymarin against 
Cisplatin nephrotoxicity in a rat model [26]. Posttreatment by 
Silymarin 2 h after Cisplatin however, significantly increase the body 
weight returning it to the normal value, yet it is failed in complete 
protection against the pathological alteration caused by Cisplatin. Pre-
treatment with Silymarin 2 h before Cisplatin significantly decreased 
the histological and ultrastructural changes induced by Cisplatin 
and appear highly protective [27]. Bokemeyer et al., found also a 
cytoprotective effect of Silymarin in the rat animal model without a 
significant inhibition of the anti-tumor activity of Cisplatin [28].
Most of other studies on Silymarin are about its protective effect on 
liver cells, such as fatty liver disease, cirrhosis, viral or autoimmune 
hepatitis. For example Féher in a review on experimental and clinical 
studies concluded that, Silymarin reduce tumor cell proliferation, 
angiogenesis and insulin resistance. In addition, it has an anti-
atherosclerotic effect, and can suppress protein production by tumor 
necrosis factor-alpha [29]. Zarban in an in vitro study found that 
powerful antioxidant effect can protect cells against oxidative stress 
[30]. Pradeep et al., in their study on rats showed that Silymarin 
exhibits significant hepatoprotective and antioxidant effect against 
diethylnitrosamine induced hepatocellular damage [31].
Present study has some limitations such as lack of placebo 
prescription in the control group, small sample size, short term 
follow-up and fixed dose of Silymarin; so, we offer to do double- 
blind studies with larger sample size, longer duration of follow-up, 
and to compare different doses and different durations of Silymarin 
administration.
cOnclusIOn 
By our knowledge, this is the first study that showed protective 
prophylaxis effect of Silymarin on Cisplatin nephrotoxicity in human. 
Based on the obtained results i.e. safety profile and minor adverse 
effect of Silymarin, we can use it as prophylaxis and probably for the 
treatment of Cisplatin nephrotoxicity in various Cisplatin- contained 
chemotherapy regimen.
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